drugset / Trial / NCT02297139

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

NCT02297139

Phase 2 Completed 17 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.

Timeline

Start
2015-07-31
Primary completion
2022-05-15
Completion
2022-05-15

Drugs

EvaluationDrugModalityDoseRoute
Background dasatinib anhydrous Small molecule